Transforming
Cancer Care
From Treating a Diagnosis
to Treating the Patient
Enabling Precision Medicine
Nathan Fowler, MD
Chief Medical Officer
MD Anderson and BostonGene Announce Strategic Alliance to Advance Personalized Cancer Diagnostics and Treatments
Strasbourg (France), Tokyo (Japan) and WALTHAM, MA–Oct. 6, 2020 – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader in IT and network technologies and BostonGene Corporation (BostonGene), a biomedical software company committed to defining optimal precision medicine-based therapies […]
BostonGene
- Identifies Optimal Treatments
- Our solution equips doctors with vital information to identify the best treatment for every patient. We link the key drivers of each tumor to the continually evolving landscape of new drugs, scientific discoveries, and predictive biomarkers.
- Utilizes Innovative Analysis
- We perform rapid, next-generation sequencing and unique integrated analysis of DNA and RNA to virtually reconstruct each cancer, allowing us to discover key tumor characteristics.
- Applies Cutting-Edge Research
- We use artificial intelligence (AI) and machine learning (ML) to continuously aggregate the latest cancer research and scientific discoveries for a single report on all actionable genomic, molecular, and clinical findings.
BostonGene Announces Cover Story in Cancer Cell
”A tumor ‘‘personality’’ test: the BostonGene MF Portrait™ serves as a roadmap to guide treatment decision-making, drawing from both the genomic and the local microenvironmental landscape of the tumor.”
Christina Curtis, PhD, MSc
Associate Professor of Medicine and Genetics
Stanford University School of Medicine
Co-Director, Molecular Tumor Board, Stanford Cancer Institute